VIDEO: Luspatercept ‘much better’ than ESAs at improving anemia in myelodysplastic syndrome
In this video, Aaron T. Gerds, MD, MS, discussed the results of the phase 3 COMMANDS study, pertaining to low-risk myelodysplastic syndrome, presented at ASCO Annual Meeting.
Gerds, assistant professor of medicine at Cleveland Clinic Taussig Cancer Institute, highlighted the study, which presented data suggesting that luspatercept (Reblozyl; Celgene, Bristol Myers Squibb) could improve quality of life in place of or addition to erythropoiesis-stimulating agent (ESA) therapy.
“The results showed that luspatercept was much better than ESAs at improving anemia in these low-risk patients with myelodysplastic syndrome, and could potentially lead to increased use of luspatercept for this population of patients,” Gerds said.
Collapse
Read more about